145 related articles for article (PubMed ID: 17921715)
1. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Cascinu S; Scartozzi M; Carbonari G; Pierantoni C; Verdecchia L; Mariani C; Squadroni M; Antognoli S; Silva RR; Giampieri R; Berardi R
Am J Clin Oncol; 2007 Oct; 30(5):526-30. PubMed ID: 17921715
[TBL] [Abstract][Full Text] [Related]
2. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
[TBL] [Abstract][Full Text] [Related]
4. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Crane CH; Mason K; Janjan NA; Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Tiberio GA; Nodari F; Strina C; Marini G
Cancer Chemother Pharmacol; 2006 Jan; 57(2):185-90. PubMed ID: 16151811
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Dragovich T; Burris H; Loehrer P; Von Hoff DD; Chow S; Stratton S; Green S; Obregon Y; Alvarez I; Gordon M
Am J Clin Oncol; 2008 Apr; 31(2):157-62. PubMed ID: 18391600
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Milla P; Zanon C
Pancreas; 2006 Jan; 32(1):44-50. PubMed ID: 16340743
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Lipton A; Harvey H; Witters L; Kerr S; Legore K; Campbell C
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):43-5. PubMed ID: 15685834
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
El-Rayes BF; Ali S; Sarkar FH; Philip PA
Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
Androulakis N; Syrigos K; Polyzos A; Aravantinos G; Stathopoulos GP; Ziras N; Mallas K; Vamvakas L; Georgoulis V;
Cancer Invest; 2005; 23(1):9-12. PubMed ID: 15779862
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
Manzione L; Romano R; Germano D
Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
[TBL] [Abstract][Full Text] [Related]
19. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M
Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
